Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: A retrospective, exploratory analysis of the CORRECT trial

The Lancet Oncology

Volumn 16, Issue 8, 2015, Pages 937-948

  Tabernero, Josep ^a   Lenz, Heinz Josef ^b   Siena, Salvatore ^c,d   Sobrero, Alberto ^e   Falcone, Alfredo ^f   Ychou, Marc ^g   Humblet, Yves ^h   Bouché, Olivier ⁱ   Mineur, Laurent ^j   Barone, Carlo ^k   Adenis, Antoine ^l   Yoshino, Takayuki ^m   Goldberg, Richard M ⁿ   Sargent, Daniel J ^o   Wagner, Andrea ^p   Laurent, Dirk ^p   Teufel, Michael ^q   Jeffers, Michael ^q   Grothey, Axel ^e   Van Cutsem, Eric ^r  

^a VALL D HEBRON UNIVERSITY HOSPITAL   (Spain)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c OSPEDALE NIGUARDA CA GRANDA   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

^e UNIVERSITY OF GENOA   (Italy)

^f UNIVERSITY HOSPITAL OF PISA   (Italy)

^g CENTRE VAL D AURELLE   (France)

^h CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

ⁱ SERVICE DE DERMATOLOGIE   (France)

^j INSTITUT SAINTE CATHERINE   (France)

^k CATHOLIC UNIVERSITY   (Italy)

^l CENTRE OSCAR LAMBRET   (France)

^m NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

ⁿ THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^o MAYO CLINIC   (United States)

^p BAYER PHARMA AG   (Germany)

^q BAYER CORPORATION   (United States)

^r UNIVERSITY HOSPITALS LEUVEN   (Belgium)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN 2; B RAF KINASE; BIOLOGICAL MARKER; CIRCULATING DNA; COLONY STIMULATING FACTOR 1; DNA; GENOMIC DNA; INTERLEUKIN 6; INTERLEUKIN 8; K RAS PROTEIN; OSTEOGENIC PROTEIN 1; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; PLACEBO; PLACENTAL GROWTH FACTOR; REGORAFENIB; SOLUBLE TIE 1 RECEPTOR; SOLUBLE VASCULOTROPIN RECEPTOR 1; STROMAL CELL DERIVED FACTOR 1; TIE 1 RECEPTOR; TISSUE INHIBITOR OF METALLOPROTEINASE 2; UNCLASSIFIED DRUG; VASCULOTROPIN A; VASCULOTROPIN A ISOFORM 121; VASCULOTROPIN C; VASCULOTROPIN D; VASCULOTROPIN RECEPTOR 1; VON WILLEBRAND FACTOR; ANTINEOPLASTIC AGENT; BRAF PROTEIN, HUMAN; CARBANILAMIDE DERIVATIVE; KRAS PROTEIN, HUMAN; ONCOPROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PIK3CA PROTEIN, HUMAN; PYRIDINE DERIVATIVE; RAS PROTEIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BRAF GENE; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; DNA DETERMINATION; DRUG RESPONSE; EVOLUTION; FEMALE; GENETIC EVOLUTION; GENOTYPE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; MULTICENTER STUDY (TOPIC); MUTATIONAL ANALYSIS; ONCOGENE K RAS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PIK3CA GENE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REAL TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDY; ADENOCARCINOMA; BLOOD; COLORECTAL NEOPLASMS; DISEASE COURSE; DISEASE FREE SURVIVAL; GENETIC PREDISPOSITION; GENETICS; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; NUCLEOTIDE SEQUENCE; PATHOLOGY; PATIENT SELECTION; PERSONALIZED MEDICINE; PHENOTYPE; PROPORTIONAL HAZARDS MODEL; SECONDARY; TIME; TREATMENT OUTCOME;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE III AS TOPIC; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INDIVIDUALIZED MEDICINE; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PATIENT SELECTION; PHENOTYPE; PHENYLUREA COMPOUNDS; PHOSPHATIDYLINOSITOL 3-KINASES; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; PYRIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RAS PROTEINS; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, TIE-1; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84938055998     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(15)00138-2     Document Type: Article

References (48)

1. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004, 351:337-345.
2. Douillard JY, Siena S, Cassidy J, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 2010, 28:4697-4705.
3. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350:2335-2342.
4. Jonker DJ, O'Callaghan CJ, Karapetis CS, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007, 357:2040-2048.
5. Kabbinavar FF, Schulz J, McCleod M, et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 2005, 23:3697-3705.
6. Kabbinavar FF, Hambleton J, Mass RD, et al. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 2005, 23:3706-3712.
7. Peeters M, Price TJ, Cervantes A, et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 2010, 28:4706-4713.
8. Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008, 26:2013-2019.
9. Joulain F, Proskorovsky I, Allegra C, et al. Mean overall survival gain with aflibercept plus FOLFIRI vs placebo plus FOLFIRI in patients with previously treated metastatic colorectal cancer. Br J Cancer 2013, 109:1735-1743.
10. Diaz LA, Williams RT, Wu J, et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 2012, 486:537-540.
11. Misale S, Yaeger R, Hobor S, et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 2012, 486:532-536.
12. Wilhelm SM, Dumas J, Adnane L, et al. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer 2011, 129:245-255.
13. Grothey A, Van Cutsem E, Sobrero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013, 381:303-312.
14. Li J, Qin S, Xu R, et al. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2015, 16:619-629.
15. Diehl F, Li M, He Y, et al. BEAMing: single-molecule PCR on microparticles in water-in-oil emulsions. Nat Methods 2006, 3:551-559.
16. Li M, Diehl F, Dressman D, Vogelstein B, Kinzler KW BEAMing up for detection and quantification of rare sequence variants. Nat Methods 2006, 3:95-97.
17. Higgins MJ, Jelovac D, Barnathan E, et al. Detection of tumor PIK3CA status in metastatic breast cancer using peripheral blood. Clin Cancer Res 2012, 18:3462-3469.
18. Janakiraman M, Vakiani E, Zeng Z, et al. Genomic and biological characterization of exon 4 KRAS mutations in human cancer. Cancer Res 2010, 70:5901-5911.
19. Smith G, Bounds R, Wolf H, et al. Activating K-Ras mutations outwith 'hotspot' codons in sporadic colorectal tumours - implications for personalised cancer medicine. Br J Cancer 2010, 102:693-703.
20. Pare-Brunet L, Sebio A, Salazar J, et al. Genetic variations in the VEGF pathway as prognostic factors in metastatic colorectal cancer patients treated with oxaliplatin-based chemotherapy. Pharmacogenomics J 2015, published online Feb 24. 10.1038/tpj.2015.1.
21. Sottoriva A, Kang H, Ma Z, et al. A Big Bang model of human colorectal tumor growth. Nat Genet 2015, 47:209-216.
22. Stintzing S, Stremitzer S, Sebio A, Lenz HJ Predictive and prognostic markers in the treatment of metastatic colorectal cancer (mCRC): personalized medicine at work. Hematol Oncol Clin North Am 2015, 29:43-60.
23. Diehl F, Schmidt K, Choti MA, et al. Circulating mutant DNA to assess tumor dynamics. Nat Med 2008, 14:985-990.
24. D'Amico G, Korhonen EA, Anisimov A, et al. Tie1 deletion inhibits tumor growth and improves angiopoietin antagonist therapy. J Clin Invest 2014, 124:824-834.
25. Rees KA, Singh H, Brindle NP The receptor tyrosine kinase Tie1 is expressed and activated in epithelial tumour cell lines. Int J Oncol 2007, 31:893-897.
26. Waldner MJ, Foersch S, Neurath MF Interleukin-6-a key regulator of colorectal cancer development. Int J Biol Sci 2012, 8:1248-1253.
27. Ning Y, Lenz HJ Targeting IL-8 in colorectal cancer. Expert Opin Ther Target 2012, 16:491-497.
28. Dewerchin M, Carmeliet P PlGF: a multitasking cytokine with disease-restricted activity. Cold Spring Harb Perspect Med 2012, 2:a011056.
29. Ellis LM, Hicklin DJ VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer 2008, 8:579-591.
30. Motoyama K, Tanaka F, Kosaka Y, et al. Clinical significance of BMP7 in human colorectal cancer. Ann Surg Oncol 2008, 15:1530-1537.
31. Mroczko B, Groblewska M, Wereszczynska-Siemiatkowska U, et al. Serum macrophage-colony stimulating factor levels in colorectal cancer patients correlate with lymph node metastasis and poor prognosis. Clin Chim Acta 2007, 380:208-212.
32. Tung SY, Chang SF, Chou MH, et al. CXC chemokine ligand 12/stromal cell-derived factor-1 regulates cell adhesion in human colon cancer cells by induction of intercellular adhesion molecule-1. J Biomed Sci 2012, 19:91.
33. Groblewska M, Mroczko B, Gryko M, et al. Serum levels and tissue expression of matrix metalloproteinase 2 (MMP-2) and tissue inhibitor of metalloproteinases 2 (TIMP-2) in colorectal cancer patients. Tumour Biol 2014, 35:3793-3802.
34. Schellerer VS, Mueller-Bergh L, Merkel S, et al. The clinical value of von Willebrand factor in colorectal carcinomas. Am J Transl Res 2011, 3:445-453.
35. Forbes SA, Bindal N, Bamford S, et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Research 2011, 39:D945-D950.
36. Van Cutsem E, Kohne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009, 360:1408-1417.
37. Bokemeyer C, Bondarenko I, Makhson A, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009, 27:663-671.
38. De Roock W, Claes B, Bernasconi D, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2010, 11:753-762.
39. Tol J, Nagtegaal ID, Punt CJ BRAF mutation in metastatic colorectal cancer. N Engl J Med 2009, 361:98-99.
40. Yamauchi M, Morikawa T, Kuchiba A, et al. Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum. Gut 2012, 61:847-854.
41. Schmieder R, Hoffmann J, Becker M, et al. Regorafenib (BAY 73-4506): Antitumor and antimetastatic activities in preclinical models of colorectal cancer. Int J Cancer 2014, 135:1487-1496.
42. Abou-Elkacem L, Arns S, Brix G, et al. Regorafenib inhibits growth, angiogenesis, and metastasis in a highly aggressive, orthotopic colon cancer model. Mol Cancer Ther 2013, 12:1322-1331.
43. Frattini M, Gallino G, Signoroni S, et al. Quantitative analysis of plasma DNA in colorectal cancer patients: a novel prognostic tool. Ann NY Acad Sci 2006, 1075:185-190.
44. Czeiger D, Shaked G, Eini H, et al. Measurement of circulating cell-free DNA levels by a new simple fluorescent test in patients with primary colorectal cancer. Am J Clin Pathol 2011, 135:264-270.
45. Eisen T, Joensuu H, Nathan PD, et al. Regorafenib for patients with previously untreated metastatic or unresectable renal-cell carcinoma: a single-group phase 2 trial. Lancet Oncol 2012, 13:1055-1062.
46. Australian Public Assessment Report: Regorafenib Australian Government Department of Health, (accessed July 8, 2015). https://www.tga.gov.au/auspar/auspar-regorafenib.
47. Snuderl M, Batista A, Kirkpatrick ND, et al. Targeting placental growth factor/neuropilin 1 pathway inhibits growth and spread of medulloblastoma. Cell 2013, 152:1065-1076.
48. Sung CY, Son MW, Ahn TS, et al. Expression of placenta growth factor in colorectal carcinomas. J Korean Soc Coloproctol 2012, 28:315-320.